Biodesix to raise $27 million in equity offering
BOULDER — Biodesix Inc.has raised $17.5 million in capital.
The Boulder-based biotech company is raising a total of $27.5 million, according to a Form D filed with the U.S. Securities and Exchange Commission on Oct. 23. The company is raising funds through an equity offering and the date of first sale was Oct. 10. Biodesix did not return a request for more information.
Biodesix makes blood-based diagnostic tests for lung-disease patients. Earlier this year, the company acquired Seattle-based Integrated Diagnostics Inc.
SPONSORED CONTENT
People Powered: Preparing Longmont Businesses for Economic Success
Longmont Chamber and FNBO present People Powered on April 24, 2024, aiming to inform business owners about workforce development, housing, and transportation issues.
BOULDER — Biodesix Inc.has raised $17.5 million in capital.
The Boulder-based biotech company is raising a total of $27.5 million, according to a Form D filed with the U.S. Securities and Exchange Commission on Oct. 23. The company is raising funds through an equity offering and the date of first sale was Oct. 10. Biodesix did not return a request for more information.
Biodesix makes blood-based diagnostic tests for lung-disease patients. Earlier this year, the company acquired Seattle-based Integrated Diagnostics Inc.
…
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
